REVIEWOpen Access

Update on the Treatment of Glucocorticoid-Induced Osteoporosis

Ai Lee Lim

Rheumatology Unit, Hospital Pulau Pinang, Penang, Malaysia

Search for more papers by this author

and

Swan Sim Yeap

https://orcid.org/0000-0002-0474-3667

Department of Medicine, Subang Jaya Medical Centre, Selangor, Malaysia

E-mail Address: swanyeap@gmail.com

Corresponding author: Swan Sim Yeap, Department of Medicine, Subang Jaya Medical Centre, No. 1, Jalan SS12/1A, 47500 Selangor, Malaysia.

Search for more papers by this author

https://doi.org/10.1142/S2661341722300038Cited by:4 (Source: Crossref)

This article is part of the issue:

SPECIAL ISSUE ON ASSESSMENT AND TREATMENT OF OSTEOPOROSIS

Abstract

Osteoporosis and osteoporotic fracture are one of the most common side effects of glucocorticoid therapy. All patients who are taking any dose of glucocorticoids for over 3 months should have a bone health assessment. After consideration of their clinical risk factors, glucocorticoid dose, bone mineral density measurement, and the Fracture Risk Assessment Tool score, patients can be stratified into low-, moderate-, and high-risk groups. General measures include optimization of calcium and vitamin D intake, reducing glucocorticoid dosage and lifestyle modifications. In patients with moderate to high risk of fracture, pharmacological agents should be prescribed, of which bisphosphonates, denosumab, and teriparatide are the most widely used.

Keywords:

References

1. Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000; 93(2) :105–11. Crossref, Google Scholar
2. Overman RA, Yeh JY, Deal CL . Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2013; 65(2) :294–8. Crossref, Google Scholar
3. Rice JB, White AG, Scarpati LM, Wan G, Nelson WW . Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017; 39(11) :2216–29. Crossref, Google Scholar
4. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13 :777–87. Crossref, Google Scholar
5. Natsui K, Tanaka K, Suda M, Yasoda A, Sakuma Y, Ozasa A, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int. 2006; 17 :105–8. Crossref, Google Scholar
6. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15 :993–1000. Crossref, Google Scholar
7. Amiche MA, Abtahi S, Driessen JH, Vestergaard P, de Vries F, Cadarette SM, et al. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos. 2018; 13 :30. Crossref, Google Scholar
8. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003; 48(11) :3224–9. Crossref, Google Scholar
9. Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, et al. Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom. 2019; 22 :453–71. Crossref, Google Scholar
10. Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012; 23 :2257–76. Crossref, Google Scholar
11. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017; 69 :1521–37. Crossref, Google Scholar
12. Leib ES, Saag KG, Adachi JD, Geusens PP, Binkley N, McCloskey EV, et al. Official positions for FRAX ⓒ clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX ⓒ of the 10-year risk of fracture: from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX ⓒ. J Clin Densitom. 2011; 14 :212–9. Crossref, Google Scholar
13. Kanis JA, Johansson H, Oden A, McCloskey EV . Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011; 22 :809–16. Crossref, Google Scholar
14. Buckley L, Humphrey MB . Glucocorticoid-induced osteoporosis. New Engl J Med. 2018; 379 :2547–56. Crossref, Google Scholar
15. Lane NE . Glucocorticoid-induced osteoporosis: new insights into the pathophysiology and treatments. Curr Osteoporos Rep. 2019; 17 :1–7. Crossref, Google Scholar
16. Adami G, Saag KG . Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019; 30 :1145–56. Crossref, Google Scholar
17. Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res. 2014; 29 :518–30. Crossref, Google Scholar
18. Leib ES, Winzenrieth R. Bone status in glucocorticoid-treated men and women. Osteoporos Int. 2016; 27 :39–48. Crossref, Google Scholar
19. Florez H, Hernandez-Rodriguez J, Muxi A, Carrasco JL, Prieto-González S, Cid MC, et al. Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology. 2020; 59 :1574–80. Crossref, Google Scholar
20. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, et al. UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998; 244(4) :271–92. Crossref, Google Scholar
21. Messina OD, Vidal LF, Vidal MV, Bultink IE, Raterman HG, Lems W. Management of glucocorticoid-induced osteoporosis. Aging Clin Exp Res. 2021; 33(4) :793–804. Crossref, Google Scholar
22. Hall G, Daniels M, Doyle D, Spector TD . Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. 1994; 37 :1499–505. Crossref, Google Scholar
23. Reid I, Wattie D, Evans M, Stapleton JP . Testosterone therapy in glucocorticoid-treated men. Arch Intern Med. 1996; 156 :1173–7. Crossref, Google Scholar
24. Kung AW, Chan TM, Lau CS, Wong RW, Yeung SS . Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy. Rheumatology (Oxford). 1999; 38(12) :1239–44. Crossref, Google Scholar
25. Allen CS, Yeung JHS, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016; 10 :CD001347. Google Scholar
26. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2001; 44 :202–11. Crossref, Google Scholar
27. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000; 67 :277–85. Crossref, Google Scholar
28. Hakala M, Kröger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, et al. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. Scand J Rheumatol. 2012; 41 :260–266. Crossref, Google Scholar
29. Deng J, Silver Z, Huang E, Zheng E, Kavanagh K, Wen A, et al. Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis. Rheumatology (Oxford). 2021; 60(2) :649–57. Crossref, Google Scholar
30. Amiche MA, Lévesque LE, Gomes T, Adachi JD, Cadarette SM . Effectiveness of oral bisphosphonates in reducing fracture risk among oral glucocorticoid users: three matched cohort analyses. J Bone Miner Res. 2018; 33(3) :419–29. Crossref, Google Scholar
31. Reid DM, Devogelaer J-P, Saag K, Roux C, Lau C-S, Reginster J-V, et al. Zolendronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy randomised controlled trial. Lancet. 2009; 373 :1253–63. Crossref, Google Scholar
32. Mok CC, Ho LY, Leung SMT, Cheung HN, Chen SPL, Ma KM . Denosumab versus alendronate in long-term glucocorticoid users: a 12-month randomized controlled trial. Bone. 2021; 146 :115902. Crossref, Google Scholar
33. Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial. Arthritis Rheumatol. 2019; 71(7) :1174–84. Crossref, Google Scholar
34. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2019; 104(5): 1595–622. Crossref, Google Scholar
35. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60(11) :3346–55. Crossref, Google Scholar
36. Richy F, Ethgen O, Bruyere O, Reginster J-Y . Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int. 2004; 15 :301–10. Crossref, Google Scholar
37. Mok CC, Ying KY, To CH, Ho LY, Yu KL, Lee HK, et al. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis. 2011; 70(5) :778–8. Crossref, Google Scholar
38. McKenzie AF, Budd RS, Yang C, Shapiro B, Hicks RJ . Technetium-99m-methylene diphosphonate uptake in the fetal skeleton at 30 weeks gestation. J Nucl Med. 1994; 35(8) :1338–41. Google Scholar
39. Sokal A, Elefant E, Leturcq T, Beghin D, Mariette X, Seror R. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. Osteoporos Int. 2019; 30(1) :221–9. Crossref, Google Scholar
40. Machairiotis N, Ntali G, Kouroutou P, Michala L. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. Horm Mol Biol Clin Investig. 2019; 40(2) :/j/hmbci.2019.40.issue-2/hmbci-2019-0021/hmbci-2019-0021.xml, https://doi.org/10.1515/hmbci-2019-0021. Google Scholar
41. Prolia full prescribing information. https://www.mims.com/malaysia/drug/info/prolia?type=full. Accessed March 31, 2022. Google Scholar
42. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al . National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017; 12(1) :43, https://doi.org/10.1007/s11657-017-0324-5. Crossref, Google Scholar
43. Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A , et al.American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update executive summary. Endocr Pract. 2020; 26(5) :564–70. Crossref, Google Scholar
44. De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP . Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007; 56 :208–14. Crossref, Google Scholar

Vol. 22, No. Supp01

Metrics

Downloaded 547 times

History

Received 16 March 2022

Accepted 17 April 2022

Published: 3 June 2022

Information

This is an Open Access article published by World Scientific Publishing Company. It is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND) License which permits use, distribution and reproduction, provided that the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Keywords

PDF download

System Upgrade on Tue, May 28th, 2024 at 2am (EDT)

Update on the Treatment of Glucocorticoid-Induced Osteoporosis

Abstract

Recommended